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Lymphoepithelioma-like cholangiocarcinoma (LELCC) is a rare variant of intrahepatic chol-
angiocarcinoma. Epstein-Barr virus (EBV) was reported to be associated with LELCC in approximately 70%
of cases by EBV-encoded small non-polyadenylated RNA (EBER) in situ hybridization. In reviewing
literature, the treatment experience of advanced LELCC are lacking. In this study, we reported a young
female patient diagnosed with locally advanced EBV-associated LELCC with elevated EBV DNA titer and
treated with systemic chemotherapy.
Copyright © 2016, The Chinese Oncology Society. Production and hosting by Elsevier B.V. All right
reserved. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Lymphoepithelioma-like cholangiocarcinoma (LELCC) is a rare
variant of intrahepatic cholangiocarcinoma. EpsteineBarr virus
(EBV) was reported to be associated with LELCC in approximately
70% of cases by EBV-encoded small non-polyadenylated RNA
(EBER) in situ hybridization. The outcome of early LELCC is reported
to be superior to classic intrahepatic cholangiocarcinoma. However,
experience with treatment for advanced LELCC is limited. In this
study, we reported a young female patient diagnosed with locally
advanced EBV-associated LELCC with elevated EBV DNA titer and
treated with systemic chemotherapy.
2. Case report
2.1. Clinical features
A 32-year-old Chinese woman presented with abdominal pain
for four weeks, accompanied by anorexia, relapsing fever, andnd Oncology, Department of
at Linkou, No.5, Fushing St.,
.
ncology Society.
Society. Production and hosting by
-Y, et al., EpsteineBarr virus
stemic chemotherapy, Journgeneral malaise. Her medical history was signiﬁcant for latent
hepatitis B infection. The patient's pain was vaguely located in the
upper abdomen, radiating to the back and progressing over time.
Blood tests were prognostically signiﬁcant for leukocytosis (WBC
30,700/mL), anemia (hemoglobin 8.3 g/dL), coagulopathy (pro-
thrombin time 16.3 s), hyperbilirubinemia (total bilirubin 2.4 mg/
dL), and elevated C-reactive protein (CRP, 228.9 mg/L).
A heterogenous liver hilar tumor was detected by abdominal
sonography. Abdominal computed tomography (CT) showed a he-
patic tumor with multiple enlarged lymph nodes at the para-aortic
area as well as splenomegaly (Fig. 1). Dilatation of intra-hepatic bile
duct was noted as well.2.2. Pathologic ﬁndings
Upon microscopic examination of the patient's core-needle bi-
opsy specimen, the hepatic tumor cells had irregular large nuclei
with syncytial growth pattern without glandular formation. The
tumor stroma was signiﬁcant with dense lymphoplasmacytic
infiltration (Fig. 2A). Immunohistochemical staining was weakly
positive for Hep Par 1 and negative for CK7, CK20 and TTF-1
(Fig. 2B). EpsteineBarr virus-encoded small non-polyadenylated
RNA (EBER) signals were shown in the nuclei of
lymphoepithelioma-like cholangiocarcinoma (Fig. 2C).Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. Abdominal computed tomography (CT) showed a heterogenous hepatic tumor
with multiple enlarged lymph nodes at the para-aortic area as well as splenomegaly.
C.-Y. Huang et al. / Journal of Cancer Research and Practice xxx (2016) 1e422.3. Treatment course
A percutaneously transhepatic cholangiographic drainage tube
was inserted into the left intra-hepatic duct to relieve obstructive
jaundice. Her serum hepatitis B DNA titer was undetected (less than
116 copies/ml), and EBV DNA titer was 598,000 copies/mL. Her
serum tumor markers were within normal limits, including car-
bohydrate antigen 19-9 (CA19-9, 17.56 U/mL), carcinoembryonic
antigen (CEA, 0.62 ng/mL) and alpha-fetoprotein (AFP, 3.4 ng/mL).
The patient underwent systemic chemotherapy of cisplatin and
gemcitabine combination treatment. After one dose of cisplatin and
one dose of gemcitabine, her serum EBV DNA titer decreased to
9090 copies/mL. However, the patient experienced esophageal
variceal bleeding at day 17 of chemotherapy. Endoscopic variceal
ligation was performed at the same time.Fig. 2. (A) The lymphoepithelioma-like cholangiocarcinoma was composed of undifferentia
Tumor cells are weakly staining of hep-par1, as compared to normal hepatocyte. Immunoh
situ hybridization X 200.
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j.jcrpr.2016.08.002The patient received subsequent gemcitabine for one cycle after
resolution of variceal bleeding. However, a subsequent CT scan
showed progression of the hepatic tumor as well as regional
lymphadenopathy. Following systemic chemotherapy of gemcita-
bine monotherapy, the patient's serum EBV DNA titer had risen
(Fig. 3). Thereafter, the patient died three months after she was
diagnosed with disease.
3. Discussion
Lymphoepithelioma-like cholangiocarcinoma is histologically
characterized by large undifferentiated cells with vesicular
nuclei, prominent nucleoli, indistinct cell borders, and dense
lymphoplasma cell inﬁltrations. In reviewing the English litera-
ture, only 27 cases of LELCC were reported. Clinical characteris-
tics and pathologic features are summarized in Table 1. In
reported cases of all 27 patients, a female-predominant (16/27)
trend is observed. The median study participant age was 57, and
about 70% (19/27) of the cases were positive with EBER in situ
hybridization. Interestingly, the geographical distribution of re-
ported cases was similar to nasopharyngeal carcinoma,1 with 69%
(20/29) of the cases arising from east and southeast parts of Asia.
How EBV infection contributes to carcinogenesis of LELCC needs
further investigation.
EpsteineBarr virus DNA in serum/plasma has been reported as a
prognostic marker for nasopharyngeal carcinoma.17 The presence
of EpsteineBarr nuclear antigen 1 (EBNA-1) DNA in peripheral
blood is a risk factor for patients with nasopharyngeal carcinoma
developing distant metastasis as well as a lower survival rate.18
Furthermore, pretreatment plasma EBV DNA copy number and
their clearance rates are also signiﬁcant predictors for treatment
outcome in patients with nasopharyngeal cancer.19 Whether EBV
DNA in peripheral blood level can be used as a prognostic factor in
patients with LELCC is notwell-deﬁned. To our knowledge, wewere
the ﬁrst researchers to report elevated serum EBV DNA in patientsted epithelial cells with abundant lymphoplasmacytic cell inﬁltration. H&E X 200. (B)
istochemical staining X 50. (C) EBER signals shown in nuclei of cholangiocarcinoma. In
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Fig. 3. Patient's EBV DNA titer (shown in Log10) and clinical course (days after diagnosis). Treatment of systemic chemotherapy with cisplatin (P) and gemcitabine (G) are also
shown in the ﬁgure.
Table 1
Summary of clinicopathological features of LELCC in the literature.
Author N Region Gender EBER positivity EBV DNA Outcome
Cases associated with EBV infection
Hsu et al,2 1996 1 Taiwan M:0, F:1 1/1 NA Died of disease at 4 years
Vortmeyer et al,3 1998 1 USA M:0, F:1 1/1 NA Local recurrence at 2 years
Ortiz et al,4 2000 1 Spain M:0, F:1 1/1 NA Died of disease at 44 months
Chen et al,5 2001 2 Taiwan M:1, F:1 1/2 NA One disease free at 8 months, one died of
post-operative complication
Jeng et al,6 2001 5 Taiwan M:2, F:3 5/5 NA Four disease free, one died of disease at 4 years
Chan et al,7 2014 7 Hong Kong M:0, F:7 7/7 NA All alive at 56e165 months
Huang, et al,8 2004 1 Taiwan M:0, F:1 1/1 NA Disease free at 24 months
This case, 2016 1 Taiwan M:0, F:1 1/1 598000 Died of disease at 3 months
Cases not associated with EBV infection
Kim et al,9 1999 1 Korea M:1, F:0 0/1 NA NA
Szekely,10 2001 1 NA M:1, F:0 0/1 NA Disease free at 11 months
Chen et al,11 2007 1 Taiwan M:1, F:0 0/1 NA Died of disease at 21 months
Adachi et al,12 2008 1 Japan M:1, F:0 0/1 NA Disease free at 3 months
Henderson et al,13 2010 1 USA M:0, F:1 0/1 NA Disease free at 6 months
Lee,14 2011 1 Korea M:1, F:0 0/1 NA Disease free at 54 months
Hur et al,15 2011 1 Korea M:0, F:1 0/1 NA Disease free at 60 months
Aosasa et al,16 2015 1 Japan M:0, F:1 0/1 NA Disease free at 20 months
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level in a patient with advanced LELCC, and clearance after initial
chemotherapy. The purpose of our study was to conﬁrm whether
peripheral blood EBV DNA level might correlate with disease pro-
gression in patients LELCC associated with EBV. Additionally, we
further intended to assess EBV DNA titer in patients with LELCC
associated with EBV.
The outcome of early LELCC is reported to be better than
classical intra-hepatic cholangiocarcinoma (IHCC). Chan et al re-
ported a seven-patient case series with surgically resected stage I
LELCC, which demonstrated better overall survival and disease-
free survival compared to randomly selected stage I IHCC.7 How-
ever, the clinical outcome and optimal treatment of advanced
LELCC remains unknown. We reported the ﬁrst Asian patient with
advanced LELCC treated with systemic chemotherapy. Gemcita-
bine, a nucleoside analog, was reported to have an objective
response rate of 0e30% as a single-agent,20 and 21e35% as com-
bination therapy with cisplatin in treating bile duct cancer.21e24 In
patients with nasopharyngeal carcinoma, gemcitabine also has an
objective response rate of 28e48% as a single-agent,25 and
64e92% as combination therapy with cisplatin.25e29 In this case,
we opted for combination therapy of cisplatin and gemcitabine for
this patient based on the literature reports. However, the result
was quite dismal despite initial EBV DNA response after one cycle
of cisplatin and gemcitabine.Please cite this article in press as: Huang C-Y, et al., EpsteineBarr virus
elevated EBV DNA titer and treated with systemic chemotherapy, Journ
j.jcrpr.2016.08.002Programmed death ligand 1 (PD-L1) expression is a character-
istic feature of EBV-associated malignancies. Research has shown
that an increase of PD-1-expressing intratumoral CD8 T cells pre-
dicts a poor prognosis for nasopharyngeal carcinoma.30 Preliminary
data from a phase Ib study, KEYNOTE-028, showed an overall
response rate of 22.2% in 27 heavily pretreated patients with
advanced nasopharyngeal carcinoma treated with pembrolizumab
(anti-PD-1 antibody), with six partial responses. LELCC was char-
acterized by dense lymphoplasmacytic inﬁltration in the tumor
stroma as seen in nasopharyngeal carcinoma, and treatment
strategy of immune checkpoint blockade appears reasonable.
However, more clinical evidence and further effective systemic
treatment should be investigated to more effectively optimize
management of advanced LELCC.Conﬂict of interest
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